Log in

NASDAQ:CCXI - ChemoCentryx Stock Price, Forecast & News

$48.00
-1.29 (-2.62 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$46.86
Now: $48.00
$49.39
50-Day Range
$34.82
MA: $41.39
$49.29
52-Week Range
$6.16
Now: $48.00
$49.97
Volume529,736 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:CCXI
CUSIP16383L10
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees76
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.


ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How were ChemoCentryx's earnings last quarter?

ChemoCentryx Inc (NASDAQ:CCXI) issued its earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating the Zacks' consensus estimate of ($0.28) by $0.06. The biopharmaceutical company earned $10.58 million during the quarter, compared to analysts' expectations of $7.83 million. View ChemoCentryx's Earnings History.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for ChemoCentryx.

What price target have analysts set for CCXI?

6 analysts have issued 1 year price targets for ChemoCentryx's stock. Their forecasts range from $22.00 to $60.00. On average, they expect ChemoCentryx's stock price to reach $44.67 in the next year. This suggests that the stock has a possible downside of 6.9%. View Analyst Price Targets for ChemoCentryx.

What is the consensus analysts' recommendation for ChemoCentryx?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.

What are Wall Street analysts saying about ChemoCentryx stock?

Here are some recent quotes from research analysts about ChemoCentryx stock:
  • 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (2/5/2020)
  • 2. HC Wainwright analysts commented, "We base our $23 price target on probability adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and use our estimated fully diluted year end 2019 net cash of $2.54/share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x." (5/7/2019)

Has ChemoCentryx been receiving favorable news coverage?

Media coverage about CCXI stock has trended somewhat positive on Sunday, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ChemoCentryx earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for ChemoCentryx.

Are investors shorting ChemoCentryx?

ChemoCentryx saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,460,000 shares, an increase of 21.2% from the January 15th total of 2,030,000 shares. Based on an average trading volume of 1,240,000 shares, the days-to-cover ratio is currently 2.0 days. Currently, 6.1% of the shares of the stock are sold short. View ChemoCentryx's Current Options Chain.

Who are some of ChemoCentryx's key competitors?

What other stocks do shareholders of ChemoCentryx own?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the folowing people:
  • Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 60)
  • Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 56)
  • Dr. Rajinder Singh, Sr. VP of Research (Age 52)
  • Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 66)
  • Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 58)

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.06%), RA Capital Management L.P. (5.51%), Farallon Capital Management LLC (2.58%), State Street Corp (1.81%), UBS Group AG (1.42%) and Renaissance Technologies LLC (1.32%). Company insiders that own ChemoCentryx stock include Geoffrey M Parker, James L Tyree, Markus J Cappel, Plc Glaxosmithkline, Pui San Kwan, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.

Which institutional investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Farallon Capital Management LLC, Acadian Asset Management LLC, UBS Group AG, Employees Retirement System of Texas, Bank of America Corp DE, Sei Investments Co. and Barclays PLC. Company insiders that have sold ChemoCentryx company stock in the last year include Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View Insider Buying and Selling for ChemoCentryx.

Which institutional investors are buying ChemoCentryx stock?

CCXI stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., FMR LLC, Lord Abbett & CO. LLC, Sofinnova Investments Inc., State Street Corp, Goldman Sachs Group Inc., Emerald Advisers LLC and Emerald Mutual Fund Advisers Trust. View Insider Buying and Selling for ChemoCentryx.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $48.00.


MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  273 (Vote Outperform)
Underperform Votes:  259 (Vote Underperform)
Total Votes:  532
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Penny Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel